CytoMed Therapeutics Limited
GDTC · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $52 | $291 | $0 | $84 |
| % Growth | -82.1% | – | -100% | – |
| Cost of Goods Sold | $23 | $3 | $81 | $3 |
| Gross Profit | $52 | $382 | -$81 | $82 |
| % Margin | 100.7% | 131.4% | – | 96.9% |
| R&D Expenses | $1,429 | $1,205 | $1,131 | $806 |
| G&A Expenses | $1,242 | $344 | $443 | $433 |
| SG&A Expenses | $1,266 | $371 | $443 | $435 |
| Sales & Mktg Exp. | $24 | $25 | $0 | $2 |
| Other Operating Expenses | -$823 | $0 | $41 | -$305 |
| Operating Expenses | $1,871 | $1,575 | $1,616 | $937 |
| Operating Income | -$2,626 | -$3,199 | -$1,697 | -$1,399 |
| % Margin | -5,049.8% | -1,101% | – | -1,661.4% |
| Other Income/Exp. Net | $739 | $122 | -$573 | -$128 |
| Pre-Tax Income | -$1,887 | -$3,077 | -$2,270 | -$1,534 |
| Tax Expense | $0 | $0 | $1 | $0 |
| Net Income | -$1,883 | -$3,132 | -$2,271 | -$1,534 |
| % Margin | -3,621.1% | -1,077.8% | – | -1,822.3% |
| EPS | -0.16 | -0.29 | -0.3 | -0.22 |
| % Growth | 44.8% | 3.3% | -36.4% | – |
| EPS Diluted | -0.16 | -0.29 | -0.3 | -0.22 |
| Weighted Avg Shares Out | 11,540 | 10,630 | 7,915 | 6,935 |
| Weighted Avg Shares Out Dil | 11,540 | 10,630 | 7,915 | 6,935 |
| Supplemental Information | – | – | – | – |
| Interest Income | $238 | $213 | $2 | $3 |
| Interest Expense | $15 | $38 | $91 | $88 |
| Depreciation & Amortization | $92 | $77 | $293 | $244 |
| EBITDA | -$1,791 | -$2,938 | -$1,095 | -$1,048 |
| % Margin | -3,443% | -1,011.1% | – | -1,244.7% |